Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24263151 | 1.00 | CNR2 (0.37) | CNR2NPSR1L3MBTL1POLBMAPK1 | |
| SCHEMBL24263116 | 0.77 | CNR2 (0.34) | CNR2NPSR1L3MBTL1POLBMAPK1 | |
| SCHEMBL24263122 | 0.77 | CNR2 (0.34) | CNR2NPSR1L3MBTL1POLBMAPK1 | |
| SCHEMBL24349877 | 0.74 | APLNR (0.34) | — | |
| SCHEMBL24349876 | 0.74 | APLNR (0.34) | — | |
| SCHEMBL24262982 | 0.73 | CA1 (0.37) | CNR2NPSR1 | |
| SCHEMBL25928849 | 0.73 | ACE (0.36) | CNR2NPSR1POLBMAPK1 | |
| SCHEMBL24263334 | 0.73 | CA1 (0.37) | CNR2NPSR1 | |
| SCHEMBL24349875 | 0.72 | POLB (0.31) | POLB | |
| SCHEMBL24349874 | 0.72 | POLB (0.31) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | GRPR, TLR3, TLR1 | CNR2 328/4885NPSR1 37/4885L3MBTL1 4794/4885 |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | LPAR1, TACR1, ADGRF1 | CNR2 361/4885NPSR1 23/4885L3MBTL1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.